

## **Supplementary Information**

### **Combination therapy with anti-HIV-1 antibodies maintains viral suppression**

#### **Supplementary Tables**

Supplementary Table 1	Antibody sensitivity pre-screening of bulk outgrowth-derived viruses
Supplementary Table 2	HIV-1 RNA levels, CD4 <sup>+</sup> T cell counts and bNAb serum levels
Supplementary Table 3	Adverse events reported during 30 weeks of study follow-up
Supplementary Table 4	Virus neutralization by 3BNC117 and 10-1074
Supplementary Table 5	Pre-Infusion IgG neutralizing activity

Supplementary Table 1. Antibody sensitivity pre-screening of bulk outgrowth-derived viruses

Study ID	Pre-Screen ID	3BNC117		10-1074		VRC01		PGT121		Pre-Screen ID	3BNC117		10-1074		VRC01		PGT121		µg/ml
		IC50	IC80	IC50	IC80	IC50	IC80	IC50	IC80		IC50	IC80	IC50	IC80	IC50	IC80	IC50	IC80	
9241	B426	0.809	2.212	0.090	0.243	19.563	>20	0.038	0.142	0758	>25	>25	4.030	16.099	NT	NT	NT	NT	< 0.5
9242	B361	0.160	0.433	0.144	0.389	NT	NT	NT	NT	B322	0.356	0.985	0.372	1.001	NT	NT	NT	NT	0.5 - 1.0
9243	B221	0.641	2.913	0.072	0.241	NT	NT	NT	NT	B324	2.458	13.304	9.247	>20	NT	NT	NT	NT	1.0 - 2.0
9244	B62	0.277	0.966	0.025	0.068	NT	NT	NT	NT	B332	0.114	0.315	0.053	0.149	NT	NT	NT	NT	2.0 - 5.0
9245	B14	0.417	1.423	0.038	0.089	NT	NT	NT	NT	B333	0.467	1.206	0.580	1.507	NT	NT	NT	NT	5.0 - 20.0
9246	B364	0.144	0.387	0.040	0.105	0.357	0.920	0.042	0.112	B339	5.766	>20	>20	>20	NT	NT	NT	NT	>20.0
9247	B247	0.556	1.930	0.072	0.326	NT	NT	NT	NT	B341	18.852	>20	8.910	>20	NT	NT	NT	NT	
9248	0154	1.863	9.738	0.676	2.252	7.141	>20	0.082	0.296	B342	3.985	12.161	0.277	0.828	NT	NT	NT	NT	
9249	0191	0.562	2.095	0.260	0.983	NT	NT	NT	NT	B356	>20	>20	6.929	>20	NT	NT	NT	NT	
9250	B432	0.558	3.174	0.447	2.644	NT	NT	NT	NT	B358	9.554	>20	0.914	3.461	NT	NT	NT	NT	
9251	B439	1.200	3.125	0.073	0.153	2.264	7.457	0.031	0.089	B359	0.371	1.102	0.056	0.150	NT	NT	NT	NT	
9252	B442	0.630	3.074	0.243	0.640	3.243	9.639	0.029	0.113	B360	0.698	2.325	2.584	>20	NT	NT	NT	NT	
9253	0230	0.558	2.644	0.020	0.317	1.093	4.851	0.013	0.124	B362	10.420	>20	1.307	10.656	>20	>20	5.497	>20	
9254	0287	0.142	0.386	0.085	0.240	0.488	2.338	0.110	0.418	B363	>20	>20	>20	>20	NT	NT	NT	NT	
9255	0115-2	0.324	0.833	0.006	0.015	1.335	6.510	0.006	0.019	B365	0.427	1.090	0.264	0.871	NT	NT	NT	NT	
	0008	1.008	3.350	>20	>20	9.041	>20	>20	>20	B366	1.960	6.948	>20	>20	NT	NT	NT	NT	
	0027	1.158	4.395	0.167	0.571	>20	>20	0.035	0.098	B369	3.841	11.274	>20	>20	14.672	>20	>20	>20	
	0030	0.894	3.088	2.086	>20	13.164	>20	0.570	5.895	B371	3.041	18.237	1.597	11.923	6.455	>20	0.798	4.385	
	0047	1.707	7.549	0.194	0.872	2.295	8.332	0.112	0.545	B372	3.694	11.404	<20	<20	<20	<20	<20	<20	
	0098	0.137	0.589	0.293	2.503	0.369	0.978	0.105	1.866	B375	0.157	0.470	0.044	0.127	0.955	2.680	0.022	0.089	
	0108	1.061	3.950	1.224	5.659	2.935	13.156	0.098	0.874	B378	>20	>20	0.732	5.515	>20	>20	0.357	1.950	
	0114	1.491	4.304	0.034	0.090	6.715	>20	0.021	0.082	B379	12.622	>20	0.058	0.159	3.440	10.588	0.178	1.521	
	0170	0.135	0.399	0.397	4.889	0.137	0.526	0.445	11.333	B381	0.894	2.435	2.541	11.160	5.532	>20	7.303	>20	
	0171	0.508	1.807	0.260	0.696	5.692	18.793	0.312	12.051	B382	>20	>20	0.123	0.328	>20	>20	0.048	0.143	
	0174	5.233	>20	0.363	0.985	2.772	8.438	0.440	1.623	B388	4.094	19.473	0.268	0.723	5.516	>20	0.056	0.217	
	0176	1.101	3.069	0.328	0.884	6.442	19.790	0.230	0.901	B389	>20	>20	0.276	0.726	0.511	1.173	0.080	0.311	
	0181	3.108	17.962	0.730	2.654	0.940	2.552	0.379	2.175	B394	1.013	5.932	0.230	1.211	2.716	17.545	0.120	0.492	
	0183	2.915	>20	0.377	1.151	0.966	5.665	0.098	0.580	B395	1.291	5.122	>20	>20	3.415	12.215	>20	>20	
	0188	1.984	8.533	0.012	0.038	>20	>20	0.008	0.021	B396	0.275	0.954	>20	>20	1.336	3.017	>20	>20	
	0190	0.324	1.018	0.110	0.376	1.904	5.811	0.089	0.335	B398	10.466	>20	>20	>20	13.222	>20	>20	>20	
	0202	0.119	0.322	>20	>20	4.211	16.063	6.874	>20	B399	1.109	3.743	1.635	5.438	2.720	10.202	1.972	17.751	
	0213	1.284	7.920	0.227	0.660	17.889	>20	0.046	0.150	B400	2.312	6.333	0.194	0.535	5.829	19.980	0.213	1.391	
	0215	1.263	4.638	0.264	1.312	15.159	>20	0.163	2.364	B401	1.530	5.645	0.946	3.235	6.686	18.312	0.112	0.671	
	0216	2.494	10.352	0.021	0.060	3.299	11.453	0.014	0.051	B402	5.356	19.911	1.209	7.226	10.439	>20	0.541	>20	
	0228	1.449	4.156	1.055	12.452	>20	>20	2.181	>20	B403	0.676	1.945	>20	>20	6.907	>20	>20	>20	
	0233	0.868	4.133	3.568	>20	>20	>20	8.644	>20	B407	0.044	0.193	0.017	0.057	0.129	0.572	0.256	7.199	
	0246	2.425	7.267	0.940	3.327	17.328	>20	0.358	1.412	B410	2.546	11.641	>20	>20	9.067	>20	>20	>20	
	0261	0.240	1.665	1.422	4.836	0.525	2.238	4.783	>20	B416	>20	>20	3.847	18.975	>20	>20	4.238	>20	
	0285	3.495	11.715	>20	>20	16.365	>20	>20	>20	B419	>20	>20	0.043	0.171	>20	>20	0.026	0.100	
	0362	0.106	0.283	0.166	>20	0.503	1.362	0.054	0.556	B420	0.217	0.570	>20	>20	0.412	1.419	>20	>20	
	0365	0.597	1.634	<0.01	0.031	NT	NT	NT	NT	B423	>20	>20	0.251	0.720	>20	>20	3.076	>20	
	0445	0.584	2.088	0.264	0.710	2.121	5.622	0.114	0.974	B424	8.567	>20	0.240	0.852	14.047	>20	0.433	2.859	
	0453	0.588	1.574	0.122	0.335	3.969	>20	0.037	0.117	B435	0.120	0.524	0.446	1.445	0.466	1.203	0.185	0.931	
	0460	>20	>20	0.114	0.417	>20	>20	0.023	0.119	B438	1.619	4.339	3.089	9.200	3.289	8.819	3.571	>20	
	0479	0.792	2.529	0.290	0.655	5.581	17.137	0.087	0.262	B440	0.215	1.072	0.057	0.195	0.822	2.890	0.011	0.054	
	0495	0.482	1.678	0.024	0.064	NT	NT	NT	NT	B441	>20	>20	0.128	0.445	>20	>20	0.166	0.898	
	0540	0.764	1.888	0.184	1.039	5.158	15.901	0.106	0.497	B443	0.275	0.762	1.017	>20	NT	NT	NT	NT	
	0551	0.316	0.685	2.246	4.900	1.670	3.791	16.193	>20	B445	6.206	>20	0.496	1.559	>20	>20	0.164	0.753	
	0578	>20	>20	0.448	0.949	0.479	1.241	0.137	0.589	B446	1.944	7.215	3.512	10.690	1.149	11.449	2.408	11.122	
	0579	>20	>20	1.118	16.215	>20	>20	0.057	0.474	B449	18.929	>20	0.046	0.101	3.487	19.057	0.033	0.169	
	0683	2.180	6.059	>25	>25	NT	NT	NT	NT	B453	0.765	2.100	0.221	0.497	3.223	9.206	0.066	0.183	
	B325	0.333	2.741	>20	>20	NT	NT	NT	NT	B460	0.211	0.589	>20	>20	1.166	4.088	>20	>20	
	B328	0.219	0.571	0.051	0.136	NT	NT	NT	NT	B462	0.254	0.687	10.251	>20	0.584	1.555	>20	>20	
	B330	0.996	2.479	0.282	0.511	NT	NT	NT	NT	B464	2.568	6.801	>20	>20	8.654	>20	>20	>20	

NT: Not tested.

Supplementary Table 2. HIV-1 RNA levels, CD4+ T cell counts and bNAb serum levels

9241	HIV-1 RNA	CD4+ T cells		3BNC117		10-1074		
				ELISA	TZM-bl	ELISA	TZM-bl	
				Q769.d22		X2088_c9 Du422.1		
Study Visit	cp/ml	cells/μl	%	μg/ml		μg/ml		
Screen	<20	702	39	-	-	-	-	-
Wk -2 (pre-infusion)	<20	-	-	-	-	-	-	-
d0 baseline	<20	515	40	<0.51	<0.4	<0.14	<0.10	-
d0 end 3BNC117	-	-	-	1,054.35	827.12	<0.14	<0.08	-
d0 end 10-1074	-	-	-	897.99	1,223.04	1,581.00	2,618.17	1,138.65
Wk 1	-	-	-	-	-	-	-	-
Wk 2	<20	550	39	-	-	-	-	-
Wk 3 baseline	<20	728	43	58.67	58.46	405.17	267.98	-
Wk 3 end 3BNC117	-	-	-	1,165.11	1,020.46	362.70	151.66	-
Wk 3 end 10-1074	-	-	-	972.02	1,372.96	1,756.70	3,969.64	1,703.16
Wk 4	<20	-	-	-	-	-	-	-
Wk 5	<20	714	38	-	-	-	-	-
Wk 6 baseline	<20	632	42	82.55	144.92	509.51	293.39	-
Wk 6 end 3BNC117	-	-	-	1,216.86	1,529.39	488.34	315.59	-
Wk 6 end 10-1074	-	-	-	1,095.42	821.14	1,810.88	7,571.18	2,946.57
Wk 7	<20	-	-	-	-	-	-	-
Wk 8	<20D	671	37	-	-	-	-	-
Wk 9	<20	-	-	109.83	138.90	754.72	416.89	-
Wk 10	<20	713	40	-	-	-	-	-
Wk 11	<20	-	-	-	-	-	-	-
Wk 12	<20	709	37	-	-	-	-	-
Wk 13	<20 D	564	40	30.33	-	437.13	-	-
Wk 14	-	-	-	-	-	-	-	-
Wk 15	<20	551	37	23.23	27.92	335.04	126.98	-
Wk 16	<20 D	602	40	-	-	-	-	-
Wk 17	<20	644	38	-	-	-	-	-
Wk 18	<20 D	773	37	12.15	4.39	184.99	51.60	-
Wk 19	<20	-	-	-	-	-	-	-
Wk 20	60	622	39	7.73	3.29	110.53	37.08	-
Wk 21	1,060	663	39	5.68	2.37	82.53	34.82	-
Wk 22	13,250	565	35	4.79	4.72	76.41	36.27	-
Wk 23	-	-	-	-	-	-	-	-
Wk 24	<20 D	766	40	2.58	1.63	58.34	19.22	-
Wk 25	-	-	-	-	-	-	-	-
Wk 26	<20 D	-	-	-	-	-	-	-
Wk 27	-	-	-	-	-	-	-	-
Wk 28	-	-	-	-	-	-	-	-
Wk 29	-	-	-	-	-	-	-	-
Wk 30	<20 D	695	41	<0.78	<0.46	19.55	4.12	-

9242	HIV-1 RNA	CD4+ T cells		3BNC117		10-1074		
				ELISA	TZM-bl	ELISA	TZM-bl	
				Q769.d22		X2088_c9 Du422.1		
Study Visit	cp/ml	cells/μl	%	μg/ml		μg/ml		
Screen	<20	699	37	-	-	-	-	-
Wk -2 (pre-infusion)	<20	-	-	-	-	-	-	-
d0 baseline	<20	654	34	<0.51	<0.24	<0.14	<0.08	-
d0 end 3BNC117	-	-	-	880.88	1,182.36	<0.14	<0.08	-
d0 end 10-1074	-	-	-	576.18	820.37	1,039.54	935.74	890.24
Wk 1	<20	-	-	97.32	-	413.44	-	-
Wk 2	<20	626	30	40.41	-	263.01	-	-
Wk 3 baseline	<20	752	34	19.80	48.71	164.23	103.41	-
Wk 3 end 3BNC117	-	-	-	608.86	540.18	143.19	69.34	-
Wk 3 end 10-1074	-	-	-	573.53	617.58	1,186.24	1,413.97	1,085.88
Wk 4	<20	-	-	114.55	-	749.80	-	-
Wk 5	<20 D	583	31	65.25	-	440.37	-	-
Wk 6 baseline	<20	621	37	43.88	73.42	332.14	197.30	-
Wk 6 end 3BNC117	-	-	-	867.45	740.95	308.54	188.27	-
Wk 6 end 10-1074	-	-	-	727.81	615.06	1,390.20	968.56	1,033.50
Wk 7	<20	-	-	132.47	-	588.80	-	-
Wk 8	<20 D	729	35	85.87	-	424.08	-	-
Wk 9	<20	-	-	48.83	38.93	372.72	173.00	-
Wk 10	<20	985	38	-	-	-	-	-
Wk 11	<20	-	-	-	-	-	-	-
Wk 12	<20	967	36	17.39	7.88	118.91	45.21	-
Wk 13	<20 D	650	33	-	-	-	-	-
Wk 14	70	676	32	8.19	7.09	94.77	30.04	-
Wk 15	9,840	549	29	8.81	6.84	79.11	26.48	-
Wk 16	65,520	520	29	4.28	2.07	50.67	24.43	-
Wk 17	-	-	-	-	-	-	-	-
Wk 18	440	620	31	4.60	1.89	44.62	10.12	-
Wk 19	-	-	-	-	-	-	-	-
Wk 20	60	650	25	1.57	0.41	11.18	4.38	-
Wk 21	-	-	-	-	-	-	-	-
Wk 22	<20	614	32	-	-	-	-	-
Wk 23	-	-	-	-	-	-	-	-
Wk 24	<20 D	610	32	<0.51	<0.36	4.27	2.28	-
Wk 25	-	-	-	-	-	-	-	-
Wk 26	-	-	-	-	-	-	-	-
Wk 27	-	-	-	-	-	-	-	-
Wk 28	-	-	-	-	-	-	-	-
Wk 29	-	-	-	-	-	-	-	-
Wk 30	<20	546	34	<0.51	<0.26	1.02	0.40	-

9243	HIV-1 RNA	CD4+ T cells		3BNC117		10-1074		
				ELISA	TZM-bl	ELISA	TZM-bl	
				Q769.d22		X2088_c9 Du422.1		
Study Visit	cp/ml	cells/μl	%	μg/ml		μg/ml		
Screen	<20	735	29	-	-	-	-	-
Wk -2 (pre-infusion)	<20 D	-	-	-	-	-	-	-
d0 baseline	<20 D	583	32	<0.78	<0.24	<0.14	<0.08	-
d0 end 3BNC117	-	-	-	802.08	1,179.19	<0.14	<0.08	-
d0 end 10-1074	-	-	-	629.02	717.64	1,126.34	1,269.81	1,933.78
Wk 1	<20	-	-	116.78	-	518.11	-	-
Wk 2	<20	423	25	90.58	-	369.16	-	-
Wk 3 baseline	<20	475	30	57.81	33.19	257.69	141.99	-
Wk 3 end 3BNC117	-	-	-	856.99	1,123.19	226.24	125.53	-
Wk 3 end 10-1074	-	-	-	695.19	689.53	1,286.31	1,041.63	1,666.22
Wk 4	<20	-	-	149.59	-	744.32	-	-
Wk 5	<20	438	27	112.90	-	615.16	-	-
Wk 6 baseline	<20	557	29	84.41	92.07	439.77	213.90	-
Wk 6 end 3BNC117	-	-	-	812.06	870.63	378.08	176.28	-
Wk 6 end 10-1074	-	-	-	733.74	688.84	1,523.91	1,119.47	1,835.93
Wk 7	<20	-	-	190.23	-	956.76	-	-
Wk 8	<20	708	24	101.70	-	718.96	-	-
Wk 9	<20	-	-	92.31	70.29	489.89	244.23	-
Wk 10	<20	484	27	-	-	-	-	-
Wk 11	<20 D	-	-	-	-	-	-	-
Wk 12	<20	545	30	36.36	50.47	295.37	118.00	-
Wk 13	<20	484	27	-	-	-	-	-
Wk 14	<20	521	27	-	-	-	-	-
Wk 15	<20	461	29	19.68	16.15	191.71	59.71	-
Wk 16	<20 D	512	24	-	-	-	-	-
Wk 17	<20	581	24	-	-	-	-	-
Wk 18	<20	529	29	9.17	3.24	85.40	38.25	-
Wk 19	<20 D	530	24	7.72	1.98	80.43	27.91	-
Wk 20	410	360	21	6.35	2.20	67.17	19.16	-
Wk 21	10,110	450	28	5.46	0.79	58.63	17.74	-
Wk 22	-	-	-	-	-	-	-	-
Wk 23	83,430	450	25	4.21	<0.36	31.27	18.19	-
Wk 24	-	-	-	-	-	-	-	-
Wk 25	410	508	20	-	-	-	-	-
Wk 26	-	-	-	-	-	-	-	-
Wk 27	540	600	26	-	-	-	-	-
Wk 28	-	-	-	-	-	-	-	-
Wk 29	-	-	-	-	-	-	-	-
Wk 30	40	466	29	1.60	<0.26	10.54	1.48	-

9244	HIV-1 RNA	CD4+ T cells		3BNC117		10-1074		
				ELISA	TZM-bl	ELISA	TZM-bl	
				Q769.d22		X2088_c9 Du422.1		
Study Visit	cp/ml	cells/μl	%	μg/ml		μg/ml		
Screen	<20	1,042	45	-	-	-	-	-
Wk -2 (pre-infusion)	<20	-	-	-	-	-	-	-
d0 baseline	<20	1,110	43	<0.51	<0.24	<0.14	<0.08	-
d0 end 3BNC117	-	-	-	815.01	746.19	<0.14	<0.08	-
d0 end 10-1074	-	-	-	665.14	880.52	1,110.71	1,943.89	1,285.69
Wk 1	<20	-	-	94.86	-	420.18	-	-
Wk 2	<20	890	45	44.55	-	301.34	-	-
Wk 3 baseline	<20	794	44	49.96	117.85	239.56	156.12	-
Wk 3 end 3BNC117	-	-	-	845.63	1,159.59	225.05	144.62	-
Wk 3 end 10-1074	-	-	-	613.62	933.57	1,414.40	1,497.30	1,108.61
Wk 4	<20	-	-	125.55	-	647.28	-	-
Wk 5	<20	1,100	44	64.47	-	313.45	-	-
Wk 6 baseline	<20	632	42	22.48	57.13	272.66	211.41	-
Wk 6 end 3BNC117	-	-	-	797.52	1,049.48	228.31	108.28	-
Wk 6 end 10-1074	-	-	-	729.40	1,033.42	1,306.48	1,175.60	1,113.89
Wk 7	<20	-	-	112.06	-	593.18	-	-
Wk 8	<20 D	1,251	37	89.28	-	472.45	-	-
Wk 9	<20	-	-	42.35	98.33	360.06	154.56	-
Wk 10	<20 D	1,162	42	-	-	-	-	-
Wk 11	<20	-	-	-	-	-	-	-
Wk 12	<20	796	44	13.25	9.45	103.62	46.75	-
Wk 13	<20	876	44	-	-	-	-	-
Wk 14	<20 D	1,037	45	7.16	4.68	81.13	25.82	-
Wk 15	<20	1,425	38	-	-	-	-	-
Wk 16	<20	767	43	-	-	-	-	-
Wk 17	<20 D	840	42	-	-	-	-	-
Wk 18	<20	865	41	0.88	<0.36	14.29	5.98	-
Wk 19	<20	1,203	38	<0.78	<0.36	14.81	5.18	-
Wk 20	130	934	39	<0.51	<0.36	9.69	3.84	-
Wk 21	9,470	742	41	<0.51	<0.36	11.63	2.54	-
Wk 22	120,330	803	37	-	<0.46	-	1.85	-
Wk 23	-	-	-	-	-	-	-	-
Wk 24	160	970	44	<0.51	<0.36	4.26	1.82	-
Wk 25	-	-	-	-	-	-	-	-



Supplementary Table 2. HIV-1 RNA levels, CD4+ T cell counts and bNAb serum levels (continued)

9249	HIV-1 RNA	CD4+ T cells		3BNC117		10-1074			
				ELISA	TZM-bl	ELISA	TZM-bl		
				Q769.d22	Q769.d22	X2088_c9	X2088_c9	Du422.1	
Study Visit	cp/ml	cells/μl	%	μg/ml		μg/ml			
Screen	<20	1,070	41	-	-	-	-	-	-
Wk -2 (pre-infusion)	<20	-	-	-	-	-	-	-	-
d0 baseline	32	860	40	<0.51	<0.40	<0.14	<0.10	-	-
d0 end 3BNC117	-	-	-	730.57	725.90	<0.14	<0.08	-	-
d0 end 10-1074	-	-	-	517.93	305.30	1,089.60	777.07	1,005.36	-
Wk 1	<20	-	-	-	-	-	-	-	-
Wk 2	127	870	39	-	-	-	-	-	-
Wk 3 baseline	325	970	43	43.22	21.72	250.30	81.41	-	-
Wk 3 end 3BNC117	-	-	-	769.67	903.00	273.37	152.89	-	-
Wk 3 end 10-1074	-	-	-	727.14	546.94	1,221.15	6,336.80	1,174.28	-
Wk 4	60,000	-	-	101.02	61.66	631.81	316.39	-	-
Wk 5	-	-	-	-	-	-	-	-	-
Wk 6	4,560	630	39	79.31	82.00	603.73	162.28	-	-
Wk 7	-	-	-	-	-	-	-	-	-
Wk 8	5,150	810	36	-	-	-	-	-	-
Wk 9	-	-	-	-	-	-	-	-	-
Wk 10	1,590	750	41	15.82	8.69	193.88	65.91	-	-
Wk 11	-	-	-	-	-	-	-	-	-
Wk 12	1,120	630	42	7.23	5.82	99.32	50.47	-	-
Wk 13	-	-	-	-	-	-	-	-	-
Wk 14	539	840	43	3.77	2.51	70.11	31.30	-	-
Wk 15	-	-	-	-	-	-	-	-	-
Wk 16	323	610	41	-	-	-	-	-	-
Wk 17	-	-	-	-	-	-	-	-	-
Wk 18	230	750	36	-	<0.28	-	5.72	-	-
Wk 19	-	-	-	-	-	-	-	-	-
Wk 20	102	530	36	-	-	-	-	-	-
Wk 21	-	-	-	-	-	-	-	-	-
Wk 22	53	650	45	-	<0.28	-	2.33	-	-
Wk 23	-	-	-	-	-	-	-	-	-
Wk 24	<20 D	770	35	<0.51	<0.28	6.24	0.88	-	-
Wk 25	-	-	-	-	-	-	-	-	-
Wk 26	<20 D	900	42	-	-	-	-	-	-
Wk 27	-	-	-	-	-	-	-	-	-
Wk 28	<20 D	880	40	-	-	-	-	-	-
Wk 29	-	-	-	-	-	-	-	-	-
Wk 30	21	620	40	<0.51	<0.26	1.31	0.36	-	-

9250	HIV-1 RNA	CD4+ T cells		3BNC117		10-1074			
				ELISA	TZM-bl	ELISA	TZM-bl		
				Q769.d22	Q769.d22	X2088_c9	X2088_c9	Du422.1	
Study Visit	cp/ml	cells/μl	%	μg/ml		μg/ml			
Screen	<20	673	37	-	-	-	-	-	-
Wk -2 (pre-infusion)	40	-	-	-	-	-	-	-	-
d0 baseline	50	550	39	<0.51	<0.40	<0.14	<0.10	-	-
d0 end 3BNC117	-	-	-	974.23	1,119.01	<0.14	<0.08	-	-
d0 end 10-1074	-	-	-	835.05	743.38	1,392.93	2,183.68	1,077.19	-
Wk 1	<20	-	-	-	-	-	-	-	-
Wk 2	<20 D	589	33	-	-	-	-	-	-
Wk 3 baseline	20	679	38	82.09	62.90	466.94	344.97	-	-
Wk 3 end 3BNC117	-	-	-	1,025.92	1,058.27	377.75	200.03	-	-
Wk 3 end 10-1074	-	-	-	878.02	948.24	1,776.33	3,908.63	1,425.91	-
Wk 4	50	-	-	-	-	-	-	-	-
Wk 5	90	637	35	-	-	-	-	-	-
Wk 6 baseline	3,700	614	36	117.71	98.42	631.50	440.44	-	-
Wk 6 end 3BNC117	-	-	-	1,039.73	908.95	632.20	308.25	-	-
Wk 6 end 10-1074	-	-	-	855.83	747.98	1,993.71	1,245.37	1,441.19	-
Wk 7	2,070	-	-	225.00	206.56	1,206.47	1,672.09	792.20	-
Wk 8	23,610	593	31	165.44	162.22	899.45	1,287.42	402.08	-
Wk 9	-	-	-	-	-	-	-	-	-
Wk 10	490	636	30	129.95	-	662.70	-	-	-
Wk 11	-	-	-	-	-	-	-	-	-
Wk 12	<20	567	32	61.79	97.88	454.75	701.58	270.90	-
Wk 13	-	-	-	-	-	-	-	-	-
Wk 14	<20 D	542	36	39.42	-	384.37	-	-	-
Wk 15	-	-	-	-	-	-	-	-	-
Wk 16	<20 D	596	30	39.96	28.24	370.49	180.61	-	-
Wk 17	-	-	-	-	-	-	-	-	-
Wk 18	-	-	-	-	-	-	-	-	-
Wk 19	-	-	-	-	-	-	-	-	-
Wk 20	20	703	37	17.80	8.76	194.42	88.13	-	-
Wk 21	-	-	-	-	-	-	-	-	-
Wk 22	-	-	-	-	-	-	-	-	-
Wk 23	-	-	-	-	-	-	-	-	-
Wk 24	30	744	34	12.94	6.90	110.40	59.37	-	-
Wk 25	-	-	-	-	-	-	-	-	-
Wk 26	-	-	-	-	-	-	-	-	-
Wk 27	-	-	-	-	-	-	-	-	-
Wk 28	-	-	-	-	-	-	-	-	-
Wk 29	-	-	-	-	-	-	-	-	-
Wk 30	40	733	35	4.52	2.21	69.22	17.78	-	-

9251	HIV-1 RNA	CD4+ T cells		3BNC117		10-1074			
				ELISA	TZM-bl	ELISA	TZM-bl		
				Q769.d22	Q769.d22	X2088_c9	X2088_c9	Du422.1	
Study Visit	cp/ml	cells/μl	%	μg/ml		μg/ml			
Screen	<20	661	39	-	-	-	-	-	-
Wk -2 (pre-infusion)	<20	-	-	-	-	-	-	-	-
d0 baseline	<20	672	40	<0.51	<0.40	1.69	<0.10	-	-
d0 end 3BNC117	-	-	-	715.25	1,068.97	n.a.	<0.10	-	-
d0 end 10-1074	-	-	-	653.97	499.50	1,219.30	1,819.97	907.76	-
Wk 1	<20	-	-	-	111.48	-	335.17	-	-
Wk 2	<20	713	38	-	54.17	-	228.95	-	-
Wk 3 baseline	<20	760	40	34.14	6.40	182.45	120.01	-	-
Wk 3 end 3BNC117	-	-	-	667.03	1,485.62	179.09	134.72	-	-
Wk 3 end 10-1074	-	-	-	676.18	602.34	1,527.88	3,037.93	1,319.69	-
Wk 4	<20	-	-	-	125.28	-	374.15	-	-
Wk 5	<20	-	-	-	-	-	-	-	-
Wk 6 baseline	200	614	41	33.34	9.18	279.29	140.94	-	-
Wk 6 end 3BNC117	-	-	-	957.09	1,678.63	187.82	165.07	-	-
Wk 6 end 10-1074	-	-	-	736.64	603.24	1,195.80	2,967.02	1,374.08	-
Wk 7	1,810	-	-	123.94	54.63	886.67	387.05	-	-
Wk 8	6,390	560	37	55.28	18.36	579.27	155.96	-	-
Wk 9	-	-	-	-	-	-	-	-	-
Wk 10	150	763	31	43.27	-	396.14	-	-	-
Wk 11	-	-	-	-	-	-	-	-	-
Wk 12	40	679	30	18.17	8.92	228.39	52.80	-	-
Wk 13	-	-	-	-	-	-	-	-	-
Wk 14	170	740	44	7.91	-	170.16	-	-	-
Wk 15	-	-	-	-	-	-	-	-	-
Wk 16	130	382	27	-	1.08	-	26.04	-	-
Wk 17	-	-	-	-	-	-	-	-	-
Wk 18	16,070	748	37	1.15	<0.46	35.90	11.14	-	-
Wk 19	-	719	33	-	-	-	-	-	-
Wk 20	370	1,044	36	<0.78	<0.46	24.09	5.70	-	-
Wk 21	-	-	-	-	-	-	-	-	-
Wk 22	280	664	30	-	-	-	-	-	-
Wk 23	-	-	-	-	-	-	-	-	-
Wk 24	40	827	38	-	<0.46	-	2.13	-	-
Wk 25	-	-	-	-	-	-	-	-	-
Wk 26	30	1,010	44	-	-	-	-	-	-
Wk 27	-	-	-	-	-	-	-	-	-
Wk 28	<20 D	1,112	34	-	-	-	-	-	-
Wk 29	-	-	-	-	-	-	-	-	-
Wk 30	<20	860	34	<0.51	<0.28	n.a.	0.10	-	-

9252	HIV-1 RNA	CD4+ T cells		3BNC117		10-1074			
				ELISA	TZM-bl	ELISA	TZM-bl		
				Q769.d22	Q769.d22	X2088_c9	X2088_c9	Du422.1	
Study Visit	cp/ml	cells/μl	%	μg/ml		μg/ml			
Screen	<20	655	39	-	-	-	-	-	-
Wk -2 (pre-infusion)	<20	-	-	-	-	-	-	-	-
d0 baseline	<20	598	35	<0.51	<0.40	<0.14	<0.10	-	-
d0 end 3BNC117	-	-	-	1,088.44	1,390.73	<0.14	<0.08	-	-
d0 end 10-1074	-	-	-	989.26	802.28	1,823.06	5,441.90	1,006.23	-
Wk 1	<20 D	-	-	-	-	-	-	-	-
Wk 2	<20	655	36	-	-	-	-	-	-
Wk 3 baseline	<20	745	32	50.38	36.98	331.73	313.42	-	-
Wk 3 end 3BNC117	-	-	-	1,073.19	1,150.10	236.82	144.59	-	-
Wk 3 end 10-1074	-	-	-	981.49	787.70	1,801.51	7,718.30	1,890.48	-
Wk 4	<20	-	-	-	-	-	-	-	-
Wk 5	<20	626	37	-	-	-	-	-	-
Wk 6 baseline	<20	632	37	89.51	84.88	821.32	265.76	-	-
Wk 6 end 3BNC117	-	-	-	1,204.82	1,081.40	807.39	305.15	-	-
Wk 6 end 10-1074	-	-	-	1,174.40	1,091.66	3,441.41	6,093.51	1,487.96	-
Wk 7	<20	-	-	-	-	-	-	-	-
Wk 8	<20	634	37	-	-	-	-	-	-
Wk 9	<20	-	-	91.24	70.38	714.24	447.90	-	-
Wk 10	<20	701	37	-	-	-	-	-	-
Wk 11	<20	-	-	-	-	-	-	-	-
Wk 12	<20	748	37	28.74	20.22	265.54	105.83	-	-
Wk 13	<20	703	37	-	-	-	-	-	-
Wk 14	<20	886	33	-	-	-	-	-	-
Wk 15	<20	654	33	12.61	7.25	191.93	53.31	-	-
Wk 16	<20	640	34	-	-	-	-	-	-
Wk 17	<20	650	34	-	-	-	-	-	-
Wk 18	<20	768	32	5.12	3.50	62.09	30.45	-	-
Wk 19	<20	719	33	-	-	-	-	-	-
Wk 20	<20	680	36	4.53	0.99	43.57	13.92	-	-
Wk 21	-	-	-	-	-	-	-	-	-
Wk 22	1,890	428	36	1.01	0.				

Supplementary Table 2. HIV-1 RNA levels, CD4+ T cell counts and bNAb serum levels (continued)

9253	HIV-1 RNA	CD4+ T cells		3BNC117		10-1074		
				ELISA	TZM-bi	ELISA	TZM-bi	
				Q769.d22	Q769.d22	X2088_c9	Du422.1	
Study Visit	cp/ml	cells/μl	%	μg/ml		μg/ml		
Screen	<20	990	36	-	-	-	-	-
Wk -2 (pre-infusion)	41	-	-	-	-	-	-	-
d0 baseline	<20 D	950	36	<0.51	<0.46	<0.14	<0.10	-
d0 end 3BNC117	-	-	-	977.53	1,019.91	<0.14	<0.08	-
d0 end 10-1074	-	-	-	822.18	1,118.61	3,101.34	1,614.08	1,022.43
Wk 1	<20	-	-	-	-	-	-	-
Wk 2	<20	910	37	-	-	-	-	-
Wk 3 baseline	63	770	34	61.42	35.19	387.61	164.75	-
Wk 3 end 3BNC117	-	-	-	858.41	826.74	373.51	110.90	-
Wk 3 end 10-1074	-	-	-	786.52	1,505.67	2,530.64	2,642.70	1,118.03
Wk 4	66	-	-	101.72	303.23	1,094.85	611.07	401.56
Wk 5	10,200	720	37	75.71	105.48	764.14	425.17	-
Wk 6	24,300	-	-	59.35	44.78	670.83	214.53	-
Wk 7	-	-	-	-	-	-	-	-
Wk 8	118	890	36	38.34	-	252.91	-	-
Wk 9	-	-	-	-	-	-	-	-
Wk 10	<20 D	1,000	36	-	-	-	-	-
Wk 11	-	-	-	-	-	-	-	-
Wk 12	<20 D	960	35	6.09	5.38	98.41	21.65	-
Wk 13	-	-	-	-	-	-	-	-
Wk 14	<20	790	40	4.02	1.75	52.43	14.76	-
Wk 15	-	-	-	-	-	-	-	-
Wk 16	<20	780	35	1.88	<0.26	32.85	5.46	-
Wk 17	-	-	-	-	-	-	-	-
Wk 18	-	-	-	-	-	-	-	-
Wk 19	-	-	-	-	-	-	-	-
Wk 20	-	-	-	-	-	-	-	-
Wk 21	-	-	-	-	-	-	-	-
Wk 22	-	-	-	-	-	-	-	-
Wk 23	-	-	-	-	-	-	-	-
Wk 24	<20 D	770	35	<0.51	<0.26	4.20	0.84	-
Wk 25	-	-	-	-	-	-	-	-
Wk 26	-	-	-	-	-	-	-	-
Wk 27	-	-	-	-	-	-	-	-
Wk 28	-	-	-	-	-	-	-	-
Wk 29	-	-	-	-	-	-	-	-
Wk 30	<20	840	35	<0.51	<0.26	1.18	0.26	-

9254	HIV-1 RNA	CD4+ T cells		3BNC117		10-1074		
				ELISA	TZM-bi	ELISA	TZM-bi	
				Q769.d22	Q769.d22	X2088_c9	Du422.1	
Study Visit	cp/ml	cells/μl	%	μg/ml		μg/ml		
Screen	<20	750	37	-	-	-	-	-
Wk -2 (pre-infusion)	<20	-	-	-	-	-	-	-
d0 baseline	<20	860	40	<0.51	<0.46	<0.14	<0.10	-
d0 end 3BNC117	-	-	-	718.34	723.03	<0.14	<0.08	-
d0 end 10-1074	-	-	-	699.73	1,116.14	2,561.83	1,659.71	827.32
Wk 1	<20	-	-	-	-	-	-	-
Wk 2	<20	980	39	-	-	-	-	-
Wk 3 baseline	<20	990	37	48.60	56.99	329.25	179.01	-
Wk 3 end 3BNC117	-	-	-	776.95	1,275.08	366.20	110.49	-
Wk 3 end 10-1074	-	-	-	723.93	1,608.25	3,052.30	1,718.51	909.49
Wk 4	<20	1,010	39	-	-	-	-	-
Wk 5	<20	930	39	-	-	-	-	-
Wk 6 baseline	<20	880	40	67.53	46.58	555.77	234.68	-
Wk 6 end 3BNC117	-	-	-	1,420.89	1,005.13	421.41	257.98	-
Wk 6 end 10-1074	-	-	-	1,416.54	729.62	2,493.10	2,040.62	-
Wk 7	<20	-	-	-	-	-	-	-
Wk 8	<20	1,240	40	-	-	-	-	-
Wk 9	<20	-	-	83.70	95.49	674.51	227.21	-
Wk 10	<20	1,030	41	-	-	-	-	-
Wk 11	<20	-	-	-	-	-	-	-
Wk 12	<20	940	40	23.42	17.09	210.17	83.16	-
Wk 13	<20	910	39	-	-	-	-	-
Wk 14	<20	940	40	-	-	-	-	-
Wk 15	<20	940	37	10.80	3.78	170.91	64.50	-
Wk 16	<20	950	39	-	-	-	-	-
Wk 17	<20	880	38	-	-	-	-	-
Wk 18	<20	880	36	6.28	1.04	90.38	26.62	-
Wk 19	<20	960	38	-	-	-	-	-
Wk 20	<20	700	35	-	-	-	-	-
Wk 21	<20	740	38	0.87	<0.26	46.30	12.83	-
Wk 22	<20	830	39	-	-	-	-	-
Wk 23	<20	820	38	-	-	-	-	-
Wk 24	<20	980	39	<0.51	<0.26	28.70	9.38	-
Wk 25	<20	1,080	38	-	-	-	-	-
Wk 26	<20	940	39	-	-	-	-	-
Wk 27	<20	920	39	-	<0.30	-	5.75	-
Wk 28	-	-	-	-	-	-	-	-
Wk 29**	<40	-	-	-	-	-	-	-
Wk 31**	<20	-	-	-	-	-	-	-

9255	HIV-1 RNA	CD4+ T cells		3BNC117		10-1074		
				ELISA	TZM-bi	ELISA	TZM-bi	
				Q769.d22	Q769.d22	X2088_c9	Du422.1	
Study Visit	cp/ml	cells/μl	%	μg/ml		μg/ml		
Screen	<20	1,500	50	-	-	-	-	-
Wk -2 (pre-infusion)	<20 D	-	-	-	-	-	-	-
d0 baseline	<20	1,360	51	<0.51	<0.46	<0.14	<0.10	-
d0 end 3BNC117	-	-	-	737.15	1,016.37	<0.14	<0.08	-
d0 end 10-1074	-	-	-	592.97	1,176.34	1,627.91	1,008.19	785.47
Wk 1	<20 D	1,420	52	-	-	-	-	-
Wk 2	<20	1,160	52	-	-	-	-	-
Wk 3 baseline	<20 D	1,460	51	40.44	59.85	390.94	166.15	-
Wk 3 end 3BNC117	-	-	-	653.65	591.22	378.73	172.97	-
Wk 3 end 10-1074	-	-	-	482.53	636.04	1,397.83	1,375.81	1,178.40
Wk 4	<20 D	-	-	-	-	-	-	-
Wk 5	<20	1,640	50	-	-	-	-	-
Wk 6 baseline	<20	1,570	50	74.99	33.40	509.23	237.12	-
Wk 6 end 3BNC117	-	-	-	1,146.24	666.34	541.54	177.31	-
Wk 6 end 10-1074	-	-	-	985.63	570.96	2,039.18	1,534.39	-
Wk 7	<20 D	-	-	-	-	-	-	-
Wk 8	<20	1,110	51	-	-	-	-	-
Wk 9	<20	-	-	66.40	30.02	658.27	273.87	-
Wk 10	<20 D	1,450	49	-	-	-	-	-
Wk 11	<20	-	-	-	-	-	-	-
Wk 12	<20	1,350	48	56.40	33.65	234.01	106.58	-
Wk 13	<20	1,470	49	-	-	-	-	-
Wk 14	<20	1,440	49	26.52	9.94	136.85	55.58	-
Wk 15	207	1,330	46	-	-	-	-	-
Wk 16	<20	1,340	48	-	-	-	-	-
Wk 17	<20 D	1,470	49	-	-	-	-	-
Wk 18	60	1,110	52	6.09	2.42	91.64	29.56	-
Wk 19	<20 D	1,420	50	-	-	-	-	-
Wk 20	<20	1,710	50	-	-	-	-	-
Wk 21	55	1,320	50	5.01	0.62	68.20	15.82	-
Wk 22	42	1,690	50	-	-	-	-	-
Wk 23	<20	1,430	49	-	-	-	-	-
Wk 24	<20	1,320	45	1.17	<0.26	35.70	7.90	-
Wk 25	<20 D	1,550	50	-	-	-	-	-
Wk 26	<20 D	1,680	50	-	-	-	-	-
Wk 27	29	-	-	-	-	-	-	-
Wk 28	<20	1,280	50	-	-	-	-	-
Wk 29	<20	1,260	51	-	-	-	-	-
Wk 30	<20	1,400	49	<0.51	<0.26	10.00	2.73	-
Wk 32***	<20	-	-	-	-	-	-	-
Wk 34***	<20	-	-	-	-	-	-	-

\* Determined using ID<sub>80</sub> and IC<sub>80</sub>.

\*\* Participant 9254 relocated following the week 27 study visit and chose to remain off ART beyond week 30. HIV-1 RNA continued to be monitored every two weeks from samples drawn at an external practice and it remained undetectable.

\*\*\* Participant 9255 chose to remain off ART beyond week 30.

Grey shaded area indicates time on antiretroviral therapy.

Yellow shaded area indicates time of viral rebound.

Green numbers indicate detectable background by ELISA. If detected, background was subtracted from subsequent results. Results within a 3-fold of the background levels were not included (n.a.).

<20 D: Plasma HIV-1 RNA detected but not quantifiable by clinical assay.

Supplementary Table 3. Adverse events reported during 30 weeks of study follow-up

Adverse Event (AE)	AEs (no.)	Severity Grade			Participants of n=15 (no.)
		Mild (no.)	Moderate (no.)	Severe (no.)	
<b>Related to 3BNC117 + 10-1074</b>					
Malaise/Fatigue	2	2	0	0	2
<b>Total related</b>	<b>2</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>2</b>
<b>Not related to 3BNC117 + 10-1074</b>					
Upper respiratory tract infection	12	6	6	0	6
Myalgia	3	3	0	0	2
Transient increase in direct bilirubin*	2	n/a	n/a	2	2
Albuminuria	1	1	0	0	1
Back pain	1	1	0	0	1
Bloating	1	1	0	0	1
Conjunctivitis	1	0	1	0	1
Malaise/Fatigue	1	1	0	0	1
Flu-like symptoms	1	1	0	0	1
Hordeolum	1	0	0	1	1
Nausea	1	1	0	0	1
Otitis media	1	0	1	0	1
Rash**	1	1	0	0	1
Transient increase in AST	1	1	0	0	1
Vomiting	1	1	0	0	1
Worsening in hypertension	1	0	0	1	1
<b>Total Not related</b>	<b>30</b>	<b>18</b>	<b>8</b>	<b>4</b>	<b>12</b>
<b>Total</b>	<b>32</b>	<b>20</b>	<b>8</b>	<b>4</b>	<b>13</b>

\* Transient elevation to 0.7 mg/dL and intermittent elevations to 0.3 mg/dL were graded as severe following the DAIDS Toxicity Table (v. 2.0).

\*\* Mild maculopapular rash that occurred at the time of viral rebound and was compatible with acute retroviral syndrome but not accompanied by systemic symptoms and resolved within two weeks of initiation of ART.

**Supplementary Table 4. Virus neutralization by 3BNC117 and 10-1074**

Participant	Source	Method	Time Point	Virus ID	3BNC117		10-1074	
					IC50	IC80	IC50	IC80
9242	Reservoir	Q2VOA	Week -2	9242_A8	0.475	1.360	0.046	0.126
	Reservoir	Q2VOA	Week -2	9242_A14	0.070	0.190	0.083	0.232
	Reservoir	Q2VOA	Week -2	9242_B2	0.558	1.487	0.047	0.102
	Reservoir	Q2VOA	Week -2	9242_E7	0.084	0.239	0.109	0.309
	Reservoir	Q2VOA	Week -2	9242_G1	0.349	1.601	0.054	0.148
	Reservoir	Q2VOA	Week -2	9242_H16	0.354	1.140	0.040	0.116
	Reservoir	Q2VOA	Week 12	9242_12D10	0.449	1.410	0.025	0.085
	Reservoir	Q2VOA	Week 12	9242_12D16	0.347	0.898	0.033	0.090
	Reservoir	Q2VOA	Week 12	9242_12E1	0.392	1.382	0.032	0.103
	Reservoir	Q2VOA	Week 12	9242_12E21	0.532	1.813	0.057	0.154
	Reservoir	Q2VOA	Week 12	9242_12F9	0.552	1.445	0.036	0.081
	Reservoir	Q2VOA	Week 12	9242_12G2	0.452	1.495	0.038	0.100
	Reservoir	Q2VOA	Week 12	9242_12G23	0.695	1.494	0.077	0.164
	Reservoir	Q2VOA	Week 12	9242_12H20	0.212	0.702	0.117	0.264
	Reservoir	Q2VOA	Week 12	9242_12L24	0.080	0.158	0.126	0.289
Rebound PBMCs	Rebound Outgrowth	Week 16	9242_R2_6	0.671	2.994	>50	>50	
Rebound PBMCs	Rebound Outgrowth	Week 16	9242_R5_1*	0.818	1.780	31.869	>50	
Rebound plasma	Pseudovirus	Week 16	9242_S21_C10	0.129	0.441	0.183	3.217	
9243	Reservoir	Q2VOA	Week -2	9243_B23	0.486	2.353	0.124	0.447
	Reservoir	Q2VOA	Week -2	9243_C19	0.862	2.340	0.073	0.197
	Reservoir	Q2VOA	Week -2	9243_C23	0.839	3.685	0.104	0.346
	Reservoir	Q2VOA	Week -2	9243_E6	2.257	7.970	0.061	0.162
	Reservoir	Q2VOA	Week -2	9243_E11	1.021	3.531	0.099	0.276
	Reservoir	Q2VOA	Week -2	9243_E24	1.206	4.474	0.040	0.122
	Reservoir	Q2VOA	Week -2	9243_F22	1.240	2.679	0.189	0.506
	Reservoir	Q2VOA	Week -2	9243_M10	2.149	16.476	0.048	0.179
	Reservoir	Q2VOA	Week -2	9243_019	1.073	3.636	0.045	0.157
	Reservoir	Q2VOA	Week 12	9243_12D20	1.150	3.766	0.082	0.259
	Reservoir	Q2VOA	Week 12	9243_12E19	1.051	3.607	0.127	0.351
	Reservoir	Q2VOA	Week 12	9243_12G2	1.093	3.617	0.078	0.172
	Reservoir	Q2VOA	Week 12	9243_12K9	1.491	4.079	0.096	0.260
	Reservoir	Q2VOA	Week 12	9243_12K18	1.806	4.692	0.213	0.551
	Reservoir	Q2VOA	Week 12	9243_12K24	1.358	6.023	0.135	0.443
	Reservoir	Q2VOA	Week 12	9243_12L14	0.843	2.968	0.078	0.261
	Reservoir	Q2VOA	Week 12	9243_12L19	1.418	4.453	0.088	0.223
	Reservoir	Q2VOA	Week 12	9243_12N5	1.709	7.948	0.177	0.588
	Reservoir	Q2VOA	Week 12	9243_12S23	3.428	12.029	0.139	0.379
	Reservoir	Q2VOA	Week 12	9243_12W13	0.507	1.300	0.059	0.151
Rebound PBMCs	Rebound Outgrowth	Week 23	9243_R6_12*	2.263	15.203	>50	>50	
Rebound PBMCs	Rebound Outgrowth	Week 23	9243_R6_13*	2.848	6.315	>50	>50	
Rebound PBMCs	Rebound Outgrowth	Week 23	9243_R6_23	2.764	13.946	>50	>50	
Rebound plasma	Pseudovirus	Week 23	9243_S28_G9	0.262	0.891	>50	>50	
9244	Reservoir	Q2VOA	Week -2	9244_A22	0.354	1.201	0.010	0.028
	Reservoir	Q2VOA	Week -2	9244_C18	0.622	1.990	0.027	0.060
	Reservoir	Q2VOA	Week -2	9244_D1	0.352	1.169	0.008	0.023
	Reservoir	Q2VOA	Week -2	9244_E17	0.374	1.303	0.006	0.022
	Reservoir	Q2VOA	Week -2	9244_E18	0.284	0.961	0.010	0.025
	Reservoir	Q2VOA	Week -2	9244_F2	0.273	0.910	0.022	0.059
	Reservoir	Q2VOA	Week -2	9244_N16	0.695	3.339	0.046	0.207
	Reservoir	Q2VOA	Week -2	9244_N24	0.440	2.598	0.055	0.219
	Reservoir	Q2VOA	Week 12	9244_12B17	0.111	0.459	0.024	0.077
	Reservoir	Q2VOA	Week 12	9244_12B18	0.317	1.029	0.017	0.036
	Reservoir	Q2VOA	Week 12	9244_12C19	0.457	3.033	0.025	0.078
	Reservoir	Q2VOA	Week 12	9244_12D11	0.367	1.262	0.031	0.082
	Reservoir	Q2VOA	Week 12	9244_12E4	0.413	1.428	0.034	0.094
	Reservoir	Q2VOA	Week 12	9244_12F15	0.231	1.239	0.012	0.024
	Reservoir	Q2VOA	Week 12	9244_12F23	0.847	3.553	0.026	0.085
	Reservoir	Q2VOA	Week 12	9244_12G21	0.597	1.630	0.016	0.030
	Reservoir	Q2VOA	Week 12	9244_12J20	0.956	2.499	0.074	0.195
	Rebound PBMCs	Rebound Outgrowth	Week 22	9244_R1_5*	1.342	4.524	0.185	0.601
	Rebound PBMCs	Rebound Outgrowth	Week 22	9244_R1_13*	2.076	6.512	0.225	0.568
	Rebound PBMCs	Rebound Outgrowth	Week 22	9244_R7_7*	0.620	2.207	0.065	0.227
	Rebound PBMCs	Rebound Outgrowth	Week 22	9244_R8_12*	1.133	2.424	0.065	0.229
	Rebound PBMCs	Rebound Outgrowth	Week 22	9244_R1_10	0.507	1.783	0.053	0.185
Rebound PBMCs	Rebound Outgrowth	Week 22	9244_R1_15	0.636	2.992	0.062	0.270	
Rebound plasma	Pseudovirus	Week 22	9244_S29_B12	0.014	0.063	0.004	0.014	
Rebound plasma	Pseudovirus	Week 22	9244_S33_A8	0.074	0.314	0.015	0.065	
Rebound plasma	Pseudovirus	Week 22	9244_S37_G9	0.064	0.270	0.011	0.035	

\* matching SGA



Supplementary Table 4 (continued). Virus neutralization by 3BNC117 and 10-1074.

Participant	Source	Method	Time Point	Virus ID	3BNC117		10-1074	
					IC50	IC80	IC50	IC80
9245	Reservoir	Q2VOA	Week -2	9245_A21	0.323	0.902	>50	>50
	Reservoir	Q2VOA	Week -2	9245_B16	0.278	1.008	0.024	0.072
	Reservoir	Q2VOA	Week -2	9245_B22	0.742	2.404	>50	>50
	Reservoir	Q2VOA	Week -2	9245_D19	0.570	1.913	>50	>50
	Reservoir	Q2VOA	Week -2	9245_E5	0.515	1.665	>50	>50
	Reservoir	Q2VOA	Week -2	9245_H1	0.389	1.625	>50	>50
	Reservoir	Pseudovirus	Week 6	9245_PV_B21	0.037	0.109	>50	>50
	Reservoir	Pseudovirus	Week 6	9245_PV_E5	0.018	0.073	>50	>50
	Rebound plasma	Pseudovirus	Week 6	9245_S40_H5	5.361	>50	>50	>50
9246	Reservoir	Q2VOA	Week -2	9246_J5	0.892	4.023	0.013	0.046
	Reservoir	Q2VOA	Week -2	9246_I10	0.104	0.293	0.017	0.040
	Reservoir	Q2VOA	Week -2	9246_B1_5	0.138	0.379	0.010	0.028
	Reservoir	Pseudovirus	Week -2	9246_PV_I10	0.011	0.036	0.006	0.020
	Reservoir	Q2VOA	Week 12	9246_12Q21	0.595	2.661	0.006	0.021
	Reservoir	Q2VOA	Week 12	9246_12P1	0.179	0.601	0.055	0.143
	Reservoir	Q2VOA	Week 12	9246_12B1_2	0.062	0.413	0.014	0.048
	Reservoir	Pseudovirus	Week 12	9246_PV_12K21	0.066	0.381	0.005	0.013
	Reservoir	Pseudovirus	Week 12	9246_PV_12P1	0.023	0.068	0.008	0.024
	Rebound plasma	Pseudovirus	Week 20	9246_S41_G2	0.047	0.130	>50	>50
	Rebound plasma	Pseudovirus	Week 20	9246_S44_A4	0.020	0.068	>50	>50
Rebound plasma	Pseudovirus	Week 20	9246_S42_F4	0.017	0.059	>50	>50	
9247	Rebound plasma	Pseudovirus	Week 27	9247_S63_C5	0.012	0.040	13.226	>50
	Rebound plasma	Pseudovirus	Week 27	9247_S65_E2	0.017	0.055	48.848	>50
9241	Reservoir	Q2VOA	Week -2	9241_B3	0.082	0.285	0.047	0.170
	Reservoir	Q2VOA	Week -2	9241_D17	0.659	1.740	0.306	0.789
	Reservoir	Q2VOA	Week -2	9241_D21	1.003	3.393	0.100	0.263
	Reservoir	Q2VOA	Week -2	9241_F12	0.205	0.652	0.126	0.334
	Reservoir	Q2VOA	Week -2	9241_F19	0.723	2.304	0.123	0.343
	Reservoir	Q2VOA	Week -2	9241_G23	0.130	0.289	0.284	0.735
	Reservoir	Q2VOA	Week -2	9241_G8	0.641	2.124	0.284	0.778
	Reservoir	Q2VOA	Week -2	9241_N8	0.629	1.630	0.278	0.890
	Reservoir	Q2VOA	Week -2	9241_N14	0.476	1.253	0.117	0.311
	Reservoir	Q2VOA	Week -2	9241_Q12	0.091	0.293	0.196	0.439
	Reservoir	Q2VOA	Week 12	9241_12BW23	0.242	0.575	0.074	0.232
	Reservoir	Q2VOA	Week 12	9241_12S21	0.612	1.626	0.216	0.671
	Reservoir	Q2VOA	Week 12	9241_12X1	0.573	1.521	0.125	0.271
	Reservoir	Q2VOA	Week 12	9241_12Y6	0.571	1.547	0.175	0.462
	Reservoir	Q2VOA	Week 12	9241_12Y13	0.727	2.473	0.018	0.050
	Rebound PBMCs	Rebound Outgrowth	Week 22	9241_R1_8*	0.854	2.206	0.682	1.777
	Rebound PBMCs	Rebound Outgrowth	Week 22	9241_R2_1	0.828	2.228	0.281	0.729
	Rebound PBMCs	Rebound Outgrowth	Week 22	9241_R2_2	1.126	2.921	0.611	1.593
Rebound plasma	Pseudovirus	Week 22	9241_S68_G11	0.106	0.371	0.058	0.207	
Rebound plasma	Pseudovirus	Week 22	9241_S68_E7	0.060	0.215	0.040	0.173	
Rebound plasma	Pseudovirus	Week 22	9241_S64_C2	0.136	0.470	0.160	0.545	
9248	Reservoir	Q2VOA	Week -2	9248_D17	1.419	3.633	1.430	3.700
	Reservoir	Q2VOA	Week -2	9248_D20	0.397	0.829	0.051	0.111
	Reservoir	Q2VOA	Week -2	9248_D22	0.942	4.149	0.436	1.133
	Reservoir	Q2VOA	Week -2	9248_F1	0.802	3.502	0.414	1.856
	Reservoir	Q2VOA	Week -2	9248_F2	1.165	5.306	0.543	1.830
	Reservoir	Q2VOA	Week -2	9248_F14	0.883	4.035	0.329	1.107
	Reservoir	Q2VOA	Week -2	9248_F20	1.039	3.430	0.317	1.538
	Reservoir	Q2VOA	Week -2	9248_G8	1.152	2.371	1.507	3.694
	Reservoir	Q2VOA	Week -2	9248_Q5	0.888	2.973	0.576	1.990
	Rebound PBMCs	Rebound Outgrowth	Week 12	9248_R5_5*	0.951	3.344	>50	>50
	Rebound PBMCs	Rebound Outgrowth	Week 12	9248_R3_20	0.918	2.868	0.405	1.265
	Rebound PBMCs	Rebound Outgrowth	Week 12	9248_R4_1	0.235	0.755	0.105	0.280
	Rebound PBMCs	Rebound Outgrowth	Week 12	9248_R6_2	1.009	7.611	0.270	2.065
	Rebound PBMCs	Rebound Outgrowth	Week 12	9248_R6_3	0.595	3.035	0.640	2.218
Rebound plasma	Pseudovirus	Week 12	9248_S59_B5	0.047	0.159	>50	>50	
9249	Reservoir	Q2VOA	Week -2	9209_C7	0.842	3.901	0.141	0.381
	Reservoir	Q2VOA	Week -2	9209_G21	>50	>50	>50	>50
	Reservoir	Q2VOA	Week -2	9209_H3	1.463	4.972	>50	>50
	Reservoir	Q2VOA	Week -2	9209_I12	0.236	0.807	>50	>50
	Rebound PBMCs	Rebound Outgrowth	Week 4	9209_R4_5*	>50	>50	>50	>50
	Rebound PBMCs	Rebound Outgrowth	Week 4	9209_R4_7*	>50	>50	>50	>50
	Rebound plasma	Pseudovirus	Week 4	9209_S51_F4	0.061	0.829	>50	>50
	Rebound plasma	Pseudovirus	Week 4	9209_S52_G6	0.078	1.638	>50	>50
Rebound plasma	Pseudovirus	Week 4	9209_S47_B1	>50	>50	>50	>50	

\* matching SGA

**Supplementary Table 4 (continued). Virus neutralization by 3BNC117 and 10-1074.**

Participant	Source	Method	Time Point	Virus ID	3BNC117		10-1074	
					IC50	IC80	IC50	IC80
9250	Reservoir	Q2VOA	Week -2	9250_D23	0.371	1.303	1.017	3.517
	Reservoir	Q2VOA	Week -2	9250_F9	0.953	6.605	0.399	3.027
	Reservoir	Q2VOA	Week -2	9250_F10	0.442	2.060	0.360	1.662
	Reservoir	Q2VOA	Week -2	9250_F11	0.815	2.680	0.681	2.224
	Reservoir	Q2VOA	Week -2	9250_H19/A21	0.619	3.008	0.478	1.791
	Reservoir	Q2VOA	Week -2	9250_M1	0.626	2.833	0.852	4.228
	Reservoir	Pseudovirus	Week -2	9250_PV_F17	0.034	0.141	0.047	0.282
	Reservoir	Pseudovirus	Week -2	9250_PV_L5	0.022	0.089	0.035	0.208
	Rebound plasma	Pseudovirus	Week 8	9250_S48_B7	0.616	1.570	>50	>50
	Rebound plasma	Pseudovirus	Week 8	9250_S48_G10	0.835	3.670	>50	>50
Rebound plasma	Pseudovirus	Week 8	9250_S50_E9	0.334	1.435	>50	>50	
9251	Reservoir	Q2VOA	Week -2	9251_G5	0.840	2.940	0.049	0.164
	Reservoir	Q2VOA	Week -2	9251_Y8	0.999	3.742	0.017	0.040
	Reservoir	Q2VOA	Week -2	9251_V18/AB24	1.301	8.811	0.049	0.195
	Reservoir	Q2VOA	Week -2	9251_AB21	10.815	>50	0.018	0.040
	Reservoir	Pseudovirus	Week -2	9251_PV_G5	0.070	0.231	0.007	0.021
	Rebound plasma	Pseudovirus	Week 8	9251_S60_H12	5.821	>50	>50	>50
	Rebound plasma	Pseudovirus	Week 8	9251_S60_H3	6.690	>50	>50	>50
Rebound plasma	Pseudovirus	Week 8	9251_S60_G11	4.079	>50	>50	>50	
9252	Reservoir	Q2VOA	Week -2	9252_D17	0.275	1.974	0.056	0.332
	Reservoir	Q2VOA	Week -2	9252_F22	0.365	1.232	0.096	0.272
	Reservoir	Q2VOA	Week -2	9252_F24	0.447	1.555	0.111	0.380
	Reservoir	Q2VOA	Week -2	9252_L4	0.566	1.557	0.120	0.336
	Reservoir	Q2VOA	Week -2	9252_R3	0.583	1.800	0.142	0.369
	Reservoir	Pseudovirus	Week -2	9252_PV_E14	0.054	0.179	0.026	0.088
	Reservoir	Pseudovirus	Week -2	9252_PV_H7	0.061	0.268	0.017	0.083
	Reservoir	Pseudovirus	Week 12	9252_PV_12Q1	0.047	0.196	0.025	0.104
	Rebound plasma	Pseudovirus	Week 22	9252_PV_S70_D5	0.026	0.072	>50	>50
Rebound plasma	Pseudovirus	Week 22	9252_PV_S71_D3	0.024	0.065	>50	>50	
9253	Reservoir	Q2VOA	Week -2	9253_H9	0.515	4.434	0.032	0.077
	Reservoir	Q2VOA	Week -2	9253_H14	0.062	0.236	0.058	0.224
	Reservoir	Q2VOA	Week -2	9253_I8	0.256	0.923	0.010	0.037
	Reservoir	Q2VOA	Week -2	9253_I11	0.985	9.621	0.382	1.776
	Reservoir	Q2VOA	Week -2	9253_J18	5.714	16.850	>50	>50
	Reservoir	Q2VOA	Week -2	9253_K5	24.827	>50	0.535	2.386
	Reservoir	Q2VOA	Week -2	9253_K6	10.219	>50	2.042	8.036
	Reservoir	Pseudovirus	Week -2	9253_PV_F22	0.235	1.012	0.447	2.835
	Reservoir	Pseudovirus	Week -2	9253_PV_J18	0.266	0.891	>50	>50
	Rebound plasma	Pseudovirus	Week 6	9253_S61_B2	0.349	1.777	>50	>50
	Rebound plasma	Pseudovirus	Week 6	9253_S61_B10	0.325	1.108	>50	>50
	Rebound plasma	Pseudovirus	Week 6	9253_S61E9	0.249	1.169	>50	>50
9254	Reservoir	Q2VOA	Week -2	9254_AH4	0.299	0.635	0.164	0.371
	Reservoir	Q2VOA	Week -2	9254_AF2/E19	0.082	0.292	0.057	0.248
	Reservoir	Q2VOA	Week 12	9254_12A5	0.126	0.372	0.083	0.164
	Reservoir	Q2VOA	Week 12	9254_12D15	0.139	0.466	0.085	0.235
	Reservoir	Q2VOA	Week 12	9254_12A4	0.175	0.482	0.109	0.293
	Reservoir	Q2VOA	Week 12	9254_12I7	0.095	0.316	0.064	0.178
	Reservoir	Pseudovirus	Week 12	9254_PV_12A5	0.013	0.044	0.014	0.048
	Reservoir	Pseudovirus	Week 12	9254_PV_12A13	0.020	0.056	0.030	0.084
9255	Reservoir	Q2VOA	Week -2	9255_A1	0.225	1.022	0.003	0.010
	Reservoir	Q2VOA	Week -2	9255_A23	0.186	0.624	0.003	0.014
	Reservoir	Q2VOA	Week -2	9255_F15	0.460	2.132	0.019	0.067
	Reservoir	Q2VOA	Week -2	9255_H19	0.285	0.980	0.015	0.052
	Reservoir	Q2VOA	Week 12	9255_12I24	0.145	0.399	0.002	0.008
	Reservoir	Q2VOA	Week 12	9255_12F12	0.602	1.818	0.020	0.058
	Reservoir	Q2VOA	Week 12	9255_12E16	0.109	0.468	0.003	0.009
	Reservoir	Q2VOA	Week 12	9255_12B6	0.218	1.029	0.001	0.005
	Reservoir	Q2VOA	Week 12	9255_12K22	0.112	0.522	0.017	0.056
	Reservoir	Pseudovirus	Week -2	9255_PV_A23	0.029	0.095	0.001	0.003
Reservoir	Pseudovirus	Week -2	9255_PV_B1	0.026	0.144	0.002	0.007	

**Supplementary Table 5. Pre-Infusion IgG neutralizing activity**

Pseudovirus	9241		9242		9243		9244		9245		9246		9247		9251		9252		9254		9255	
	IC <sub>50</sub> *	IC <sub>80</sub> *	IC <sub>50</sub>	IC <sub>80</sub>	IC <sub>50</sub>	IC <sub>80</sub>	IC <sub>50</sub>	IC <sub>80</sub>	IC <sub>50</sub>	IC <sub>80</sub>	IC <sub>50</sub>	IC <sub>80</sub>	IC <sub>50</sub>	IC <sub>80</sub>	IC <sub>50</sub>	IC <sub>80</sub>	IC <sub>50</sub>	IC <sub>80</sub>	IC <sub>50</sub>	IC <sub>80</sub>	IC <sub>50</sub>	IC <sub>80</sub>
<b>Q769.d22</b>	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500
<b>TRO.11</b>	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500
<b>Q259.d2.17</b>	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500
<b>25710-2.43</b>	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	<b>474</b>	>500	>500	>500	>500	>500	>500	>500
<b>YU2.DG</b>	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	<b>140</b>	>500
<b>ZM135M.PL10a</b>	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500
<b>CNE8</b>	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500
<b>Q842.d12</b>	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500
<b>X1632_S2_B10</b>	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	<b>453</b>	>500	>500	>500	>500	>500	>500	>500
<b>Ce1176_A3</b>	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500
<b>246-F3_C10_2</b>	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500
<b>CNE55</b>	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500
<b>MuLV</b>	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500	>500

\* µg/ml